Title: Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine
Authors: Verbeken, Gilbert
Pirnay, Jean-Paul
De Vos, Daniel
Jennes, Serge
Zizi, Martin
Lavigne, Rob
Casteels, Minne
Huys, Isabelle # ×
Issue Date: Jun-2012
Publisher: Zakład Narodowy im. Ossolińskich Wydawnictwo Polskiej Adademii Nauk
Series Title: Archivum Immunologiae et Therapiae Experimentalis vol:60 issue:3 pages:161-172
Abstract: For practitioners at hospitals seeking to use natural (not genetically modified, as appearing in nature) bacteriophages for treatment of antibiotic-resistant bacterial infections (bacteriophage therapy), Europe's current regulatory framework for medicinal products hinders more than it facilitates. Although many experts consider bacteriophage therapy to be a promising complementary (or alternative) treatment to antibiotic therapy, no bacteriophage-specific framework for documentation exists to date. Decades worth of historical clinical data on bacteriophage therapy (from Eastern Europe, particularly Poland, and the former Soviet republics, particularly Georgia and Russia, as well as from today's 27 EU member states and the US) have not been taken into account by European regulators because these data have not been validated under current Western regulatory standards. Consequently, applicants carrying out standard clinical trials on bacteriophages in Europe are obliged to initiate clinical work from scratch. This paper argues for a reduced documentation threshold for Phase 1 clinical trials of bacteriophages and maintains that bacteriophages should not be categorized as classical medicinal products for at least two reasons: (1) such a categorization is scientifically inappropriate for this specific therapy and (2) such a categorization limits the marketing authorization process to industry, the only stakeholder with sufficient financial resources to prepare a complete dossier for the competent authorities. This paper reflects on the current regulatory framework for medicines in Europe and assesses possible regulatory pathways for the (re-)introduction of bacteriophage therapy in a way that maintains its effectiveness and safety as well as its inherent characteristics of sustainability and in situ self-amplification and limitation.
ISSN: 0004-069X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Division of Gene Technology (-)
Department of Pharmaceutical & Pharmacological Sciences - miscellaneous
Research Centre for Pharmaceutical Care and Pharmaco-economics (-)
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
ArchivumReprint.pdf Published 238KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science